Present disclose provides what is indicated by Formulas I to condense 1,4- oxygen azepine and related analogs: and its pharmaceutically acceptable salt, hydrate and solvate, wherein R1, R2a, R2b, R3a, R3b, R4, R5, A and Y be as noted in the discussion. Present disclosure also relates to the purposes that compound of formula I is used to treat the patients condition or illness (such as cancer) in response to the inhibition of BET bromine structural domains.
